RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 03 2020
20 03 2020
Historique:
received:
01
05
2019
accepted:
03
03
2020
entrez:
22
3
2020
pubmed:
22
3
2020
medline:
7
1
2021
Statut:
epublish
Résumé
Breast cancer risk is reduced by number of pregnancies and breastfeeding duration, however studies of breast changes during or after pregnancy are rare. Breast volume changes - although not linked to breast cancer risk - might be an interesting phenotype in this context for correlative studies, as changes of breast volume vary between pregnant women. Serum receptor activator of nuclear factor kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG) were measured prospectively before gestational week 12, and three-dimensional breast volume assessments were performed. A linear regression model including breast volume at the start of pregnancy, RANKL, OPG, and other factors was used to predict breast volume at term. The mean breast volume was 413 mL at gestational week 12, increasing by a mean of 99 mL up to gestational week 40. In addition to body mass index and breast volume at the beginning of pregnancy, RANKL and OPG appeared to influence breast volume with a mean increase by 32 mL (P = 0.04) and a mean reduction by 27 mL (P = 0.04), respectively. Linking the RANKL/RANK/OPG pathway with breast volume changes supports further studies aiming at analysing breast changes during pregnancy with regard to breast cancer risk.
Identifiants
pubmed: 32198488
doi: 10.1038/s41598-020-62070-3
pii: 10.1038/s41598-020-62070-3
pmc: PMC7083828
doi:
Substances chimiques
Osteoprotegerin
0
RANK Ligand
0
TNFRSF11B protein, human
0
TNFSF11 protein, human
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5171Références
Fasching, P. A. et al. Breast Cancer Risk - Genes, Environment and Clinics. Geburtsh Frauenheilk 71, 1056–1066, https://doi.org/10.1055/s-0031-1280437 (2011).
doi: 10.1055/s-0031-1280437
pubmed: 25253900
Wunderle, M. et al. Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. Geburtshilfe Frauenheilkd. 78, 481–492, https://doi.org/10.1055/a-0603-4350 (2018).
doi: 10.1055/a-0603-4350
pubmed: 29880983
pmcid: 5986564
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360, 187–195, https://doi.org/10.1016/S0140-6736(02)09454-0 (2002).
doi: 10.1016/S0140-6736(02)09454-0
Lambe, M. et al. Transient Increase in the Risk of Breast Cancer after Giving Birth. N. Engl. J. Med. 331, 5–9 (1994).
doi: 10.1056/NEJM199407073310102
Hack, C. C. et al. Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis. Breast cancer Res. Treat. 166, 701–708, https://doi.org/10.1007/s10549-017-4446-7 (2017).
doi: 10.1007/s10549-017-4446-7
pubmed: 28828694
Heusinger, K. et al. Mammographic density as a risk factor for breast cancer in a German case-control study. Eur. J. Cancer Prev. 20, 1–8, https://doi.org/10.1097/CEJ.0b013e328341e2ce (2011).
doi: 10.1097/CEJ.0b013e328341e2ce
pubmed: 21102341
Vachon, C. M., Kuni, C. C., Anderson, K., Anderson, V. E. & Sellers, T. A. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control. 11, 653–662 (2000).
doi: 10.1023/A:1008926607428
Gram, I. T., Funkhouser, E. & Tabar, L. Reproductive and menstrual factors in relation to mammographic parenchymal patterns among perimenopausal women. Br. J. Cancer 71, 647–650 (1995).
doi: 10.1038/bjc.1995.128
Bartow, S. A., Pathak, D. R., Mettler, F. A., Key, C. R. & Pike, M. C. Breast mammographic pattern: a concatenation of confounding and breast cancer risk factors. Am. J. Epidemiol. 142, 813–819 (1995).
doi: 10.1093/oxfordjournals.aje.a117720
Kaufman, Z., Garstin, W. I., Hayes, R., Michell, M. J. & Baum, M. The mammographic parenchymal patterns of nulliparous women and women with a family history of breast cancer. Clin. Radiol. 43, 385–388 (1991).
doi: 10.1016/S0009-9260(05)80565-3
Rauh, C. et al. Percent Mammographic Density and Dense Area as Risk Factors for Breast Cancer. Geburtsh Frauenheilk 72, 727–733, https://doi.org/10.1055/s-0032-1315129 (2012).
doi: 10.1055/s-0032-1315129
pubmed: 25258465
Loehberg, C. R. et al. Assessment of mammographic density before and after first full-term pregnancy. Eur. J. Cancer Prev. 19, 405–412, https://doi.org/10.1097/CEJ.0b013e32833ca1f4 (2010).
doi: 10.1097/CEJ.0b013e32833ca1f4
pubmed: 20700056
Asselin-Labat, M. L. et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465, 798–802, https://doi.org/10.1038/nature09027 (2010).
doi: 10.1038/nature09027
pubmed: 20383121
Joshi, P. A. et al. Progesterone induces adult mammary stem cell expansion. Nature 465, 803–807, https://doi.org/10.1038/nature09091 (2010).
doi: 10.1038/nature09091
pubmed: 20445538
Schramek, D. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468, 98–102, https://doi.org/10.1038/nature09387 (2010).
doi: 10.1038/nature09387
pubmed: 20881962
pmcid: 3084017
Gonzalez-Suarez, E. et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468, 103–107, https://doi.org/10.1038/nature09495 (2010).
doi: 10.1038/nature09495
pubmed: 20881963
Heusinger, K. et al. Association of mammographic density with hormone receptors in invasive breast cancers: results from a case-only study. Int. J. Cancer 131, 2643–2649, https://doi.org/10.1002/ijc.27515 (2012).
doi: 10.1002/ijc.27515
pubmed: 22392346
Hack, C. C. et al. Correlation of mammographic density and serum calcium levels in patients with primary breast cancer. Cancer Med. 6, 1473–1481, https://doi.org/10.1002/cam4.1066 (2017).
doi: 10.1002/cam4.1066
pubmed: 28464481
pmcid: 5463083
Koch, M. C. et al. Breast volumetry using a three-dimensional surface assessment technique. Aesthetic plastic Surg. 35, 847–855, https://doi.org/10.1007/s00266-011-9708-x (2011).
doi: 10.1007/s00266-011-9708-x
Bayer, C. M. et al. Assessment of breast volume changes during human pregnancy using a three-dimensional surface assessment technique in the prospective CGATE study. Eur. J. Cancer Prev. 23, 151–157, https://doi.org/10.1097/CEJ.0b013e3283651ccb (2014).
doi: 10.1097/CEJ.0b013e3283651ccb
pubmed: 24100511
Kiechl, S. et al. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget 8, 3811–3825, https://doi.org/10.18632/oncotarget.14013 (2017).
doi: 10.18632/oncotarget.14013
pubmed: 28002811
Kiechl, S. et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109, 2175–2180, https://doi.org/10.1161/01.CIR.0000127957.43874.BB (2004).
doi: 10.1161/01.CIR.0000127957.43874.BB
pubmed: 15117849
Kiechl, S. et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 116, 385–391, https://doi.org/10.1161/CIRCULATIONAHA.106.686774 (2007).
doi: 10.1161/CIRCULATIONAHA.106.686774
pubmed: 17620507
Salmen, J. et al. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast cancer Res. Treat. 148, 143–151, https://doi.org/10.1007/s10549-014-3130-4 (2014).
doi: 10.1007/s10549-014-3130-4
pubmed: 25253172
Hassiotou, F. & Geddes, D. Anatomy of the human mammary gland: Current status of knowledge. Clin. Anat. 26, 29–48, https://doi.org/10.1002/ca.22165 (2013).
doi: 10.1002/ca.22165
pubmed: 22997014
Hennighausen, L. & Robinson, G. W. Signaling pathways in mammary gland development. Dev. Cell 1, 467–475 (2001).
doi: 10.1016/S1534-5807(01)00064-8
Hennighausen, L. & Robinson, G. W. Information networks in the mammary gland. Nat. Rev. Mol. Cell Biol. 6, 715–725, https://doi.org/10.1038/nrm1714 (2005).
doi: 10.1038/nrm1714
pubmed: 16231422
Jud, S. M. et al. Correlates of mammographic density in B-mode ultrasound and real time elastography. Eur. J. Cancer Prev. 21, 343–349, https://doi.org/10.1097/CEJ.0b013e32834e3214 (2012).
doi: 10.1097/CEJ.0b013e32834e3214
pubmed: 22123663
Cox, D. B., Kent, J. C., Casey, T. M., Owens, R. A. & Hartmann, P. E. Breast growth and the urinary excretion of lactose during human pregnancy and early lactation: endocrine relationships. Exp. Physiol. 84, 421–434 (1999).
doi: 10.1111/j.1469-445X.1999.01807.x
Daly, S. E. et al. The determination of short-term breast volume changes and the rate of synthesis of human milk using computerized breast measurement. Exp. Physiol. 77, 79–87 (1992).
doi: 10.1113/expphysiol.1992.sp003584
Aghaeepour, N. et al. A proteomic clock of human pregnancy. Am. J. Obstet. Gynecol. 218, 347 e341–347 e314, https://doi.org/10.1016/j.ajog.2017.12.208 (2018).
doi: 10.1016/j.ajog.2017.12.208
Tanos, T. et al. Progesterone/RANKL is a major regulatory axis in the human breast. Sci. Transl. Med. 5, 182ra155, https://doi.org/10.1126/scitranslmed.3005654 (2013).
doi: 10.1126/scitranslmed.3005654
Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41–50 (2000).
doi: 10.1016/S0092-8674(00)00103-3
Sigl, V., Jones, L. P. & Penninger, J. M. RANKL/RANK: from bone loss to the prevention of breast cancer. Open Biol 6, https://doi.org/10.1098/rsob.160230 (2016).
doi: 10.1098/rsob.160230
Moran, O. et al. Serum osteoprotegerin levels and mammographic density among high-risk women. Cancer Causes Control. 29, 507–517, https://doi.org/10.1007/s10552-018-1035-y (2018).
doi: 10.1007/s10552-018-1035-y
pubmed: 29679262
Sigl, V. et al. RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res. 26, 761–774, https://doi.org/10.1038/cr.2016.69 (2016).
doi: 10.1038/cr.2016.69
pubmed: 27241552
pmcid: 5129883
Nolan, E. et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat. Med. 22, 933–939, https://doi.org/10.1038/nm.4118 (2016).
doi: 10.1038/nm.4118
pubmed: 27322743
Oden, L. et al. Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Oncotarget 7, 86687–86694, https://doi.org/10.18632/oncotarget.13417 (2016).
doi: 10.18632/oncotarget.13417
pubmed: 27893411
pmcid: 5349945
Francis, P., Singer, C., Saunders, C., Garber, J. & Lindeman, G. J. BRCA-P: An international randomised phase III study evaluating the RANK ligand inhibitor denosumab for the prevention of breast cancer in BRCA1 mutation carriers [2018–2022], http://purl.org/au-research/grants/nhmrc/1140715 and, https://researchdata.ands.org.au/brca-p-an-mutation-carriers/1319302 accessed April 28, 2019.
Schneeweiss, A. et al. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 78, 246–259, https://doi.org/10.1055/s-0044-101614 (2018).
doi: 10.1055/s-0044-101614
pubmed: 29576630
pmcid: 5862553
King, M. C., Levy-Lahad, E. & Lahad, A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 312, 1091–1092, https://doi.org/10.1001/jama.2014.12483 (2014).
doi: 10.1001/jama.2014.12483
pubmed: 25198398